BRAF and cutaneous melanoma: Prior to 2011, when the first immune checkpoint inhibitors and BRAF targeting medications were approved by the United States Food and Drug Administration (FDA), data from the Surveillance, Epidemiology, and End Results (SEER) program showed a 5-year survival of 16.1% for patients with distant metastases from cutaneous melanoma.